Additionally, Gupta et al. (2000) showed that treatment of prostate cancer with various concentrations of EGCG (20, 40, and 80 μM) could pronounce notable effects on G0/G1 phase arrest and cause cellular death by upregulation of p21 waf1 expression [121]. Here, CDKN1A is linked to prostate cancer.